Protara Therapeutics

Protara is committed to advancing transformative therapies for cancer and rare disease patients. Protara's portfolio includes its lead programs TARA-002 and IV Choline Chloride, the former being a cell-based investigational therapy for the treatment of non-muscle invasive bladder cancer and lymphatic malformations, and the latter an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure-associated liver disease.